Laekna Inc
02105
Company Profile
Business description
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers. Laekna has two Core Products and other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer.
Contact
No. 3-2-467, 5 Xingbin Road (Lin Li Center
Sino-Italy Ningbo Ecological Park
Zhejiang Province
Yuyao201203
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
83
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,829.50 | 17.30 | 0.20% |
| CAC 40 | 8,046.60 | 59.11 | 0.74% |
| DAX 40 | 24,614.53 | 306.61 | 1.26% |
| Dow JONES (US) | 49,686.12 | 159.95 | 0.32% |
| FTSE 100 | 10,387.83 | 64.08 | 0.62% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 26,090.73 | 134.41 | -0.51% |
| Nikkei 225 | 60,550.59 | 265.36 | -0.44% |
| NZX 50 Index | 12,974.32 | 211.40 | 1.66% |
| S&P 500 | 7,403.05 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,604.70 | 23.10 | 0.27% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |